”Oh right, the convenient OUR EXPECTATION clause. So when Jackie Fairley finally fesses up to the sheep (most likely at the 2022 AGM), that the conclusion of the Phase 2 DEP-Docetaxel is delayed for the umpteenth time, and says she ‘expects’ the trial will conclude in first half of 2023, shareholders should not get too excited right? Because ‘expect’ could mean 2024 or 2025 or in fact never. Do I understand your rationale @Wingmann ? It should be obvious to any fair-minded person that DEP-Docetaxel is a dud. This is my opinion.” ~ @sarge17
